Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Sheffield, Julia M.
Karcher, Nicole R.
and
Barch, Deanna M.
2018.
Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective.
Neuropsychology Review,
Vol. 28,
Issue. 4,
p.
509.
Lipner, Emily
Murphy, Shannon K.
and
Ellman, Lauren M.
2019.
Prenatal Maternal Stress and the Cascade of Risk to Schizophrenia Spectrum Disorders in Offspring.
Current Psychiatry Reports,
Vol. 21,
Issue. 10,
El-Mallakh, Rif S.
Rhodes, T. Patrick
and
Dobbins, Katharine
2019.
The Case for Case Management in Schizophrenia.
Professional Case Management,
Vol. 24,
Issue. 5,
p.
273.
Alfimova, M. V.
Kondratiev, N. V.
Golov, A. K.
and
Golimbet, V. E.
2019.
DNA Methylation at the Schizophrenia and Intelligence GWAS-Implicated MIR137HG Locus May Be Associated with Disease and Cognitive Functions.
Russian Journal of Genetics,
Vol. 55,
Issue. 2,
p.
232.
Li, Ling
Zhuang, Yingliang
Zhao, Xingsen
and
Li, Xuekun
2019.
Long Non-coding RNA in Neuronal Development and Neurological Disorders.
Frontiers in Genetics,
Vol. 9,
Issue. ,
Lin, An-Sheng
Chan, Hung-Yu
Peng, Ying-Chieh
and
Chen, Wei J.
2019.
Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study.
BMC Psychiatry,
Vol. 19,
Issue. 1,
Green, Michael F.
Horan, William P.
and
Lee, Junghee
2019.
Nonsocial and social cognition in schizophrenia: current evidence and future directions.
World Psychiatry,
Vol. 18,
Issue. 2,
p.
146.
Kelly, Sinead
Guimond, Synthia
Lyall, Amanda
Stone, William S.
Shenton, Martha E.
Keshavan, Matcheri
and
Seidman, Larry J.
2019.
Neural correlates of cognitive deficits across developmental phases of schizophrenia.
Neurobiology of Disease,
Vol. 131,
Issue. ,
p.
104353.
Grunina, Maria N.
Belinskaia, Mariia A.
Zhuravlev, Alexander S.
Nasyrova, Regina F.
Krupitsky, Evgeny M.
Taraskina, Anastasiya E.
and
Zabotina, Anna M.
2020.
Aberrant alternative splicing of HTR2A exon II in peripheral blood lymphocytes of drug-naïve schizophrenic patients.
Heliyon,
Vol. 6,
Issue. 12,
p.
e05809.
Cui, Huiru
Giuliano, Anthony J.
Zhang, Tianhong
Xu, Lihua
Wei, Yanyan
Tang, Yingying
Qian, Zhenying
Stone, Lena M.
Li, Huijun
Whitfield-Gabrieli, Susan
Niznikiewicz, Margaret
Keshavan, Matcheri S.
Shenton, Martha E.
Wang, Jijun
and
Stone, William S.
2020.
Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: Associations with clinical outcomes.
Schizophrenia Research,
Vol. 226,
Issue. ,
p.
138.
Dolleman-van der Weel, M.J.
and
Witter, M.P.
2020.
The thalamic midline nucleus reuniens: potential relevance for schizophrenia and epilepsy.
Neuroscience & Biobehavioral Reviews,
Vol. 119,
Issue. ,
p.
422.
Ryu, Jehkwang
Jung, Jae Hoon
Kim, Jiheon
Kim, Chan-Hyung
Lee, Hwa-Bock
Kim, Do-Hoon
Lee, Sang-Kyu
Shin, Ji-Hyeon
and
Roh, Daeyoung
2020.
Outdoor cycling improves clinical symptoms, cognition and objectively measured physical activity in patients with schizophrenia: A randomized controlled trial.
Journal of Psychiatric Research,
Vol. 120,
Issue. ,
p.
144.
Gandara, Veronica
Pineda, Jaime A
Shu, I-Wei
and
Singh, Fiza
2020.
A Systematic Review of the Potential Use of Neurofeedback in Patients With Schizophrenia.
Schizophrenia Bulletin Open,
Vol. 1,
Issue. 1,
Grunina, M. N.
Zabotina, A. M.
Zhuravlev, A. S.
Pchelina, M. M.
Volkova, E. V.
Nasyrova, R. F.
Taraskina, A. E.
and
Krupitsky, E. M.
2020.
DOPAMINE RECEPTOR D2 (DRD2) IN PERIPHERAL BLOOD LYMPHOCYTES AS BIOMARKER OF RESPONSE TO ANTIPSYCHOTIC MEDICATION.
The Scientific Notes of the Pavlov University,
Vol. 27,
Issue. 1,
p.
45.
Keshavan, Matcheri S.
Collin, Guusje
Guimond, Synthia
Kelly, Sinead
Prasad, Konasale M.
and
Lizano, Paulo
2020.
Neuroimaging in Schizophrenia.
Neuroimaging Clinics of North America,
Vol. 30,
Issue. 1,
p.
73.
Suárez-Méndez, Samuel
García-de la Cruz, Dulce Dajheanne
Tovilla-Zárate, Carlos Alfonso
Genis-Mendoza, Alma Delia
Ramón-Torres, Rosa Angélica
González-Castro, Thelma Beatriz
and
Juárez-Rojop, Isela Esther
2020.
Diverse roles of mtDNA in schizophrenia: Implications in its pathophysiology and as biomarker for cognitive impairment.
Progress in Biophysics and Molecular Biology,
Vol. 155,
Issue. ,
p.
36.
Alexander, Amit
Agrawal, Mukta
Bhupal Chougule, Mahavir
Saraf, Shailendra
and
Saraf, Swarnlata
2020.
Nanopharmaceuticals.
p.
175.
De la Serna, E.
Camprodon-Boadas, P.
Ilzarbe, D.
Sugranyes, G.
Baeza, I.
Moreno, D.
Díaz-Caneja, C.M.
Rosa-Justicia, M.
Llorente, C.
Ayora, M.
Borras, R.
Torrent, C.
Bernardo, M.
and
Castro-Fornieles, J.
2020.
Neuropsychological development in the child and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder: A two-year follow-up comparative study.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 103,
Issue. ,
p.
109972.
Koszła, Oliwia
Targowska-Duda, Katarzyna M.
Kędzierska, Ewa
and
Kaczor, Agnieszka A.
2020.
In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia.
Biomolecules,
Vol. 10,
Issue. 1,
p.
160.
Stone, William S.
Cai, Bing
Liu, Xinhua
Grivel, Margaux M.-R.
Yu, Gary
Xu, Yangmu
Ouyang, Xinyi
Chen, Hanhui
Deng, Fei
Xue, Fang
Li, Huijun
Lieberman, Jeffrey A.
Keshavan, Matcheri S.
Susser, Ezra S.
Yang, Lawrence H.
and
Phillips, Michael R.
2020.
Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China.
JAMA Psychiatry,
Vol. 77,
Issue. 11,
p.
1116.